Stay updated with breaking news from Nasdaq Spro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totalling 680,200 shares, a drop of 13.8% from the December 31st total of 789,000 shares. Based on an average daily volume of 171,200 shares, the days-to-cover ratio […]
In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in...
$95 million in development milestones payable over two years, as part of GSK license agreement...
Cantor Fitzgerald reissued their overweight rating on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Spero Therapeutics’ FY2024 earnings at ($0.85) EPS. Separately, HC Wainwright restated a buy rating and set a $7.00 price objective on shares of Spero Therapeutics […]
Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.39 and traded as low as $1.14. Spero Therapeutics shares last traded at $1.17, with a volume of 166,122 shares traded. Wall Street Analyst Weigh In […]